Effect of the artesunate mefloquine fixed dose combination in the malaria transmission in Amazon basin communities.

From:
Foreign, Commonwealth & Development Office
Published
1 January 2009
Country:
Brazil
Document Type:
Conference Paper
Theme:
Health
First published:
1 January 2009
Authors:
Ribeiro, I.

Abstract

This presentation describes a study of the use of the new fixed-dose antimalarial combination ASMQ (artesunate + mefloquine) in Acre state in the Amazon region of Brazil. There was a significant reduction in the number of malaria cases, the ratio of Plasmodium falciparum cases to P. vivax cases, and the recurrence rate; there were no reports of serious adverse effects and only one non-serious adverse event. It is concluded, subject to the limitations of the study, that the trial was successful.

Citation

Presentation from 鈥楾he ASMQ Fixed-Dose Combination to treat Malaria: From Blueprint to Use in the Field鈥�. Symposium from American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 19 November 2009.

Updates to this page

Published 1 January 2009
Contents